The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism

Clin Endocrinol (Oxf). 2013 Mar;78(3):330-7. doi: 10.1111/cen.12092.


Obesity, secondary (hypogonadotrophic) hypogonadism (SH), sleep disorders [such as obstructive sleep apnoea (OSA)] and type 2 diabetes mellitus (T2DM) in men have complex interlinks both with respect to mutual aetiopathogenesis as well as therapeutics. Correction of the attendant hypogonadism in obese men may serve to break this link and have beneficial effects beyond restoration of normal sexual function. Male obesity-associated secondary hypogonadism (MOSH) should be regarded as a distinct clinical entity and subtype of SH. A high index of suspicion for the presence of MOSH must be maintained by clinicians when assessing obese men. The pathogenesis of MOSH remains incompletely understood. Furthermore, the optimal management of MOSH and its associated sequelae will require long-term prospective studies that in turn will inform the development of future clinical guidelines for this important and prevalent condition.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology*
  • Humans
  • Hypogonadism / epidemiology
  • Hypogonadism / metabolism
  • Hypogonadism / pathology*
  • Male
  • Obesity / epidemiology
  • Obesity / metabolism
  • Obesity / pathology*
  • Sleep Apnea, Obstructive / epidemiology
  • Sleep Apnea, Obstructive / metabolism
  • Sleep Apnea, Obstructive / pathology